Artiria Medical secures funding to complete its clinical studies in stroke in both Europe and the US following promising first in-human results and FDA clearance.

Artiria Medical, a Swiss neurovascular MedTech company developing next-generation neuro-interventional products for stroke and aneurysms, is thrilled to announce the successful closing of a Series A2 round of USD 6M and the securing of a USD 0.6M Fit Tech Growth loan.

Artiria’s leading product is a novel real-time deflectable guidewire that enables Neurointerventional surgeons to access the diseased site faster. The product has already been used in humans and treated its first patients in the third quarter of 2023 while gaining significant traction from physicians in the neurointerventional setting.

This Series A2 investment round, led by 4FOX Ventures, was joined by the Wyss Center for Bio and Neuroengineering, and existing investors including Verve Ventures, the Zürcher Kantonalbank, NEST pension fund, and business angels.

“This funding round shall enable Artiria to study the unique features of our product with key opinion leaders in both Europe and the US through a randomized controlled study against the market leading products.” said Guillaume Petit-Pierre, CEO and co-founder of Artiria. “Following the already secured FDA clearance, this study will further enable Artiria to apply for European market approval thus significantly extending the scope of the company.”

Valentin Chenaux General Partner of 4FOX Ventures commented “We believe that Artiria’s innovative solution will advance the treatment of stroke with a product enabling safe yet accelerated procedures and we are delighted to be part of this great journey.”

About Artiria Medical

Artiria Medical was incorporated in 2019 as a spin-off of the Swiss Federal Institute of Technology in Lausanne (EPFL) with the vision of revolutionizing minimally invasive surgical interventions for the better treatment of stroke patients. Artiria’s leading product has recently obtained FDA clearance and entered first-in-human clinical studies.

Since its incorporation, Artiria Medical has been supported by various programs and institutions, including the Gebert Rüf Foundation, Venture Lab (Venture Kick & Venture Leaders programs), the European Union’s Horizon 2020 research and innovation program (EIC), the State Secretariat for Education, Research and Innovation (SERI), the Swiss National Science Foundation (BRIDGE), the Service de la promotion de l’économie et de l’innovation (SPEI), Innosuisse, and the Foundation for Technological Innovation (FIT). Artiria Medical won numerous prestigious awards, including the 1st price of Mass Challenge Switzerland (2019).

Contact information                                                                       

Artiria Medical SA, Switzerland